Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 21, 2026
TickeronGET DAILY SIGNALS
DexCom (DXCM) Pulls Back -9.4% Over the Past Month Despite Solid Fundamentals

DexCom (DXCM) Pulls Back -9.4% Over the Past Month Despite Solid Fundamentals

Key Takeaways

  • DexCom shares traded near $80 in late October, down roughly 9.4% over the trailing 30 days after slipping from about $89 in mid-September.
  • The pullback has unfolded despite solid fundamentals: second-quarter 2026 revenue rose 13% year over year, and the company raised the low end of its full-year guidance.
  • Several analysts turned more constructive in October, including Barclays (initiated Overweight with a $115 target) and price-target increases from Mizuho, BTIG, and RBC.
  • DexCom is scheduled to report third-quarter 2026 results on October 29, making the upcoming print a key near-term catalyst.
  • Competitive dynamics in the continuous glucose monitoring (CGM) market, led by Abbott and Medtronic, remain central to the investment debate.

Current Market Snapshot

DXCM shares have drifted lower over the past month, giving back some of the gains that followed a strong second-quarter earnings report. After trading near $89 in mid-September, the stock has declined roughly 9.4% to trade around $80, marking one of the weaker stretches for the shares in recent months.

The move has come against a backdrop of uneven sentiment across the medical devices sector, where concerns over healthcare policy, tougher year-over-year comparisons, and a volatile macro environment have weighed on valuations. Even so, the analyst community has largely remained constructive on DXCM, with several firms raising price targets or initiating coverage in October. That disconnect—solid fundamentals and improving sell-side sentiment versus a softening share price—frames the current setup ahead of the company's next earnings release. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

DexCom (DXCM) Business Overview and Competitive Position

DexCom, Inc. is a San Diego–based medical technology company that pioneered and now leads the market for continuous glucose monitoring (CGM) systems. Founded in 1999, the company designs, manufactures, and markets wearable sensors that deliver real-time glucose readings to smartphones and smartwatches, helping people with diabetes and their care teams manage the condition more effectively.

The company's product portfolio centers on its Dexcom G6, G7, and G7 15 Day CGM systems, alongside Stelo, the first over-the-counter CGM cleared by the U.S. Food and Drug Administration. DexCom is also advancing a next-generation G8 platform and expanding internationally, where it has posted faster growth than in its core U.S. market. Investors follow the stock for its recurring, sensor-driven revenue model, expanding margins, and its position as a leader in a category with a large, underpenetrated addressable population. From what I see, the recurring revenue angle continues to stand out as a key strength.

Recent Developments Driving DXCM

DexCom's most recent earnings report, released in late July for the second quarter of 2026, showed revenue of about $1.31 billion, up 13% year over year, with U.S. revenue up 11% and international revenue up 19%. The company raised the low end of its full-year revenue outlook to a range of $5.18 billion to $5.25 billion and lifted margin guidance, and the stock rose roughly 8% in the following session.

Since then, the focus has shifted to product expansion and the broader CGM competitive landscape. In June 2026, the FDA cleared the Stelo sensor for children, making it the first over-the-counter CGM available for pediatric prediabetic and diabetic patients. DexCom also presented data from its CONNECT trial at the 2026 American Diabetes Association Scientific Sessions, showing meaningful A1C reductions in people with type 2 diabetes not using insulin.

In October, sell-side activity picked up. Barclays initiated coverage with an Overweight rating and a $115 price target, while BTIG raised its target to $96 from $90, Mizuho to $100 from $95, and RBC to $105, each citing growth potential in the CGM market. Analysts have also flagged potential headwinds, including tougher revenue comparisons and procedure-volume pressures tied to Affordable Care Act and Medicaid policy shifts. I’m watching this closely as the October 29 report approaches.

2026 Outlook and What Investors Should Watch

Looking ahead, DexCom's guidance calls for revenue of $5.18 billion to $5.25 billion in 2026, or roughly 11% to 13% growth, supported by continued adoption of the G7 15 Day sensor, the expansion of Stelo, and further international penetration. Over the longer term, the company has outlined targets through 2030 that include annual organic growth exceeding 10% and meaningful gross and operating margin expansion.

Investors will be watching several factors closely: the pace of G7 15 Day adoption, progress on the G8 platform, the competitive response from Abbott's FreeStyle Libre franchise and Medtronic, and any shifts in reimbursement or healthcare policy. Macro conditions—including interest rates and broader market volatility—as well as the October 29 earnings release, will also shape sentiment in the near term. As always, the company's ability to sustain double-digit growth while defending its margins will be central to the stock's trajectory.

Exploring AI Tools for Market Analysis

One tool I’ve found useful in my own research is Tickeron’s AI Trading Bots. It allows me to review automated strategies across different risk profiles and timeframes, helping identify signals that align with broader fundamental views like those around DXCM. This kind of platform can complement traditional analysis when evaluating setups ahead of events such as earnings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DXCM

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


DXCM in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 21, 2026

DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 35 cases where DXCM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 22 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 200 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DXCM as a result. In 58 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The Moving Average Convergence Divergence Histogram (MACD) for DXCM turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.

DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of medical devices and glucose monitoring systems

Industry MedicalNursingServices

Industry
Medical Specialties
Address
6340 Sequence Drive
Phone
+1 858 200-0200
Employees
11100
Web
https://www.dexcom.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.